# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal

# Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa ID1505

### Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
Amryt Pharma (Oleogel-S10)	All Wales Therapeutics and
	Toxicology Centre
Patient/carer groups	Allied Health Professionals
<ul> <li>Action for Sick Children</li> </ul>	Federation
British Skin Foundation	Board of Community Health
Changing Faces	Councils in Wales
• DEBRA	British National Formulary
Let's Face It	Care Quality Commission
Muslim Council of Britain	Department of Health, Social
South Asian Health Foundation	Services and Public Safety for
Specialised Healthcare Alliance	Northern Ireland
	Healthcare Improvement Scotland
Professional groups	Medicines and Healthcare products
Association of Paediatric	Regulatory Agency
Emergency Medicines	<ul> <li>National Association of Primary Care</li> </ul>
<ul> <li>British Association for Immediate Care</li> </ul>	
_	<ul> <li>National Pharmacy Association</li> <li>NHS Alliance</li> </ul>
<ul> <li>British Association of Dermatologists</li> <li>British Dermatological Nursing</li> </ul>	NHS Confederation
Group	<ul> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>British Geriatrics Society</li> </ul>	<ul> <li>Welsh Health Specialised Services</li> </ul>
<ul> <li>British Society for Cutaneous Allergy</li> </ul>	Committee
<ul> <li>British Trauma Society</li> </ul>	
<ul> <li>National Diagnostic Epidermolysis</li> </ul>	Possible comparator companies
Bullosa Laboratory	None
Primary Care Dermatology Society	
Royal College of Emergency	Relevant research groups
Medicine	British Epidermo-Epidemiology
Royal College of General	Society
Practitioners	Centre of Evidence-based
Royal College of Nursing	Dermatology, University of
Royal College of Paediatrics & Child	Nottingham
Health	Cochrane Skin Group
Royal College of Pathologists	Cochrane Wounds Group
Royal College of Physicians	Genetic Skin Disease Group, King's
Royal Pharmaceutical Society	College London
	Genomics England

Provisional stakeholder list for the technology appraisal for Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa ID1505. Issue Date: July 2020 © National Institute for Health and Care Excellence 2020. All rights reserved Pa

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Royal Society of Medicine</li> <li>St John's Institute of Dermatology</li> <li>Surgical Dressing Manufacturers Association</li> <li>UK Clinical Pharmacy Association</li> </ul>	<ul> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Skin Treatment &amp; Research Trust</li> <li>Wounds UK</li> </ul>
Others•Department of Health and Social Care•NHS East Riding of Yorkshire CCG•NHS England•NHS Harringey CCG•Welsh Government	<ul> <li><u>Associated Public Health Groups</u></li> <li>Public Health England</li> <li>Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## Definitions:

## **Consultees**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.